The company currently has approximately 40 proprietary and partnered programs in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.

Ablynx has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Genzyme, Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceutical.